European Specialty Pharma is the Focus for Novo Growth Equity - Again
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo's $30 million investment in Orexo, following its $60 million financing of Archimedes, shows appeal of European specialty pharma.